About Dr. Andre Goy, M.D., M.S.
Dr. Goy is the Chair of oncology for Hackensack Meridian Health, the largest health care network (18 hospitals) in New Jersey. Dr. Goy also leads its tertiary care program. John Theurer Cancer Center, the largest oncology program in NJ at Hackensack University Medical Center a member of Memorial Sloan Kettering - Hackensack Meridian Partnership. John Theurer Cancer Center was also recognized this year as a Member of the NCI designated Georgetown Lombardi Comprehensive Cancer Center Consortium, one of only 16 such consortia in the US (other examples being Dana Farber Cancer Institute and Mass General or University of Washington and Fred Hutch in Seattle). He is Professor and Founding Chair of the Department of Oncology, at Hackensack Meridian School of Medicine at Seton Hall as well as Professor of Medicine at Georgetown University in DC.
Dr. Goy is widely-known for his work in lymphoma, particularly in developing novel therapies for lymphoma (drug development especially in mantle cell lymphoma and other aggressive lymphomas) as well as better ways to stratify patients with lymphoma based on prognostic markers and molecular features. Dr Goy has been on the steering committee for the NCI for lymphoma and on the scientific advisory board of the Lymphoma Research Foundation.
John Theurer Cancer Center is widely known for his blood cancers program with over 7000 bone marrow transplantations performed and was the first center in NJ to initiate and be qualified for CART cell therapy (a form of gene therapy to unleash the immune system against cancer cells).
Dr. Goy believes that a true revolution is happening in cancer medicine, which will be driven by cell-based therapies/immunotherapy, precision medicine, connectivity and analytics. The bioinformatics platform developed at JTCC® called COTA® uses a unique classification system compressing all relevant individual patient data into a usable code (CNA). This digital architecture allows to track the digital journey of every cancer patient, reduce variance, optimize treatment decisions, and improve outcome at the individual level, while lowering costs for the population along the way and supporting value-based care initiatives.
Dr. Goy has published over 180 peer reviewed papers and serves as reviewer for many journals in the field including New England Journal of Medicine, Journal of Clinical Oncology, and Blood, - the American Society of Hematology Journal, among others. He has been the co-chair of the Global Council on the Future of Health and Healthcare for the World Economic Forum since 2015. He believes that we are at an inflection point in medicine due to the unprecedented combination of exponential acceleration in science and discovery, but also technology which will help reshape both health and healthcare delivery.
Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France before completing his training in hematology oncology in Paris at the Faculté of Medicine Cochin Port Royal. While there, he also received a Master’s in Tumor Immunology from Pasteur Institute and Curie University Paris VI as well as a Master’s degree in Experimental Oncology from University Kremlin Bicetre. Dr. Goy was on faculty at Memorial Sloan-Kettering and M.D. Anderson Cancer Center before joining John Theurer Cancer Center in 2005.
Andre Goy, M.D., Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network
HACKENSACK, N.J., June 9, 2020 — Hackensack Meridian Health has announced the appointment of Andre Goy, M.D., M.S., as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service. In this role, he oversees the delivery of cancer care across the entire Hackensack Meridian Health network, the largest cancer program in New Jersey.
Dr. Goy has been chairman and executive director of John Theurer Cancer Center at Hackensack University Medical Center since 2011 and chair of oncology for Hackensack Meridian Health since 2016. He is also professor of medicine at Georgetown University and professor and chair of oncology at Seton Hall?Hackensack Meridian School of Medicine. Under his leadership, John Theurer Cancer Center became a member of the Georgetown Lombardi Comprehensive Cancer Center Consortium — one of only 16 research consortia in the nation approved by the National Cancer Institute.
As chief of the Division of Lymphoma since 2005 and holder of the Lydia Pfund Chair for Lymphoma since 2017, he has led New Jersey’s largest program focused on the research and treatment of all types of lymphoma — including Hodgkin disease, non-Hodgkin lymphoma, mantle cell lymphoma, and HIV-associated lymphoma. An internationally renowned lymphoma clinician and researcher, Dr. Goy has trained and/or worked at leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute in Paris.
Dr. Goy is widely known for his work on novel therapies for mantle cell lymphoma, having been principal investigator or co-investigator of the studies behind all four drugs approved to treat mantle cell lymphoma. He first showed evidence of activity of the drug bortezomib in recurrent or persistent mantle cell lymphoma, and then led the pivotal trial of lenalidomide for this disease while participating in the development of both BTK inhibitors ibrutinib and acalabrutinib. These novel agents are transforming the treatment of this disease, which often becomes resistant to standard therapy and has a very poor outcome.
Dr. Goy also initiated CAR T-cell therapy at John Theurer Cancer Center, in collaboration with the team of Steve Rosenberg at the National Cancer Institute. CAR T cell is a form of cellular therapy where a patient?s own immune cells are genetically engineered to force them to attack cancer cells. CAR T cells became the first live therapy approved in 2017 for aggressive lymphoma and leukemia. It is recognized as a revolutionary treatment that is now being expanded to the treatment of other lymphomas, multiple myeloma, and hopefully soon for solid tumors.
He has published extensively and serves as reviewer for many prestigious journals, including New England Journal of Medicine, Journal of Clinical Oncology, Blood, and others. He has co-chaired the Global Council on the Future of Health and Healthcare for the World Economic Forum. Dr. Goy believes that the world is at an inflection point in medicine due exponential and converging advances in science, discovery, and technologies, including artificial intelligence and augmented reality, which will help reshape health monitoring and totally transform care delivery. He has been invited to speak and teach across the globe.
"Thanks to Andre Goy's leadership, John Theurer Cancer Center has flourished to become one of the nation's leading cancer care and research centers, and that expertise now extends throughout our entire network," noted Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. "With Dr. Goy at the helm as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, patients and physicians throughout the state will benefit from his acumen and vision."
Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France before completing his training in hematology oncology in Paris at the Faculty of Medicine Cochin Port Royal. While there, he also received master’s degrees in Tumor Immunology from the Pasteur Institute and in Experimental Oncology from Kremlin Bicetre. Dr. Goy then served on the faculty at Memorial Sloan Kettering Cancer Center and M.D. Anderson Cancer Center before coming to John Theurer Cancer Center.
For more information, please contact Katherine Emmanouilidis, Director, Communications & Public Relations, 551-996-3764.
# # #
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University Medical Center is New Jersey?s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers.
The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients.
Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey.
John Theurer Cancer Center is a member of the Georgetown Lombardi Comprehensive Cancer Center Consortium, one of just 16 NCI-approved cancer research consortia based at the nation’s most prestigious institutions. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities.
For additional information, please visit www.jtcancercenter.org.
ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.
Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers — Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children’s hospitals - Joseph M. Sanzari Children?s Hospital in Hackensack, K. Hovnanian Children?s Hospital in Neptune; nine community hospitals ? Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital — Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.
Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 35,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The network’s notable distinctions include having four hospitals among the top in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker’s Healthcare’s “150 Top Places to Work in Healthcare/2019” list.
The Hackensack Meridian School of Medicine at Seton Hall University opened in 2018, the first private medical school in New Jersey in more than 50 years, welcomed its second class of 96 students in 2019 to its ON3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.
Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.
###
Physicians’ Education Resource® Announces Andre Goy as the Recipient of the 2019 PER® Educator of the Year
CRANBURY, N.J.--(BUSINESS WIRE)--Nov 19, 2019--
Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), honored Andre H. Goy, M.D., of John Theurer Cancer Center at Hackensack University Medical Center, with the 2019 Educator of the Year award during the 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow meeting. The ceremony took place on Wednesday, Nov. 6 at the New York Marriott Marquis in New York City.
“We are so honored to recognize fantastic, dynamic and knowledgeable clinicians and researchers like Dr. Goy through the PER® Educator of the Year award,” said Phil Talamo, president of PER®. “On behalf of PER, we thank Dr. Goy for his tremendous spirit and commitment as a teacher, mentor, enthusiast, and overall gentleman in collaborative education for the treatment of cancers.”
Goy is the chairman and executive director of John Theurer Cancer Center at Hackensack University Medical Center. As chief of the division of lymphoma, he leads New Jersey’s largest program for lymphoma treatment, management and research. He holds the position of Professor and Chair of the oncology department at the Seton Hall - Hackensack Meridian School of Medicine.
The PER® Educator of the Year award highlights the accomplishments of oncology leaders and honors their contributions and efforts to propel the field of medical oncology through innovative and collaborative education.
For more information, click here or find us on Twitter @gotoPER or on Facebook @gotoper.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
PER® Media Contact
Alexandra Ventura, 609-716-7777, ext. 121
aventura@mjhassoc.com